In this context, a subgroup of HER2+ BC patients with particularly poor clinical outcomes were found to express a variety of truncated HER2 fragments of 90 to 115 kDa [44,45] that have been found to drive metastasis [46] and refractoriness to trastuzumab [47]. The gene discussed is ERBB2; the disease is breast cancer.